Default from neoadjuvant chemotherapy in premenopausal female breast cancer patients: What is to blame?

Nigerian Journal of Clinical Practice

Volumn 15, Issue 3, 2012, Pages 265-269

  Egwuonwu, O A ^a   Anyanwu, S N C ^b   Nwofor, A M E ^b  

^a FEDERAL MEDICAL CENTER   (Nigeria)

^b NNAMDI AZIKIWE UNIVERSITY   (Nigeria)

Author keywords

Default; Neoadjuvant chemotherapy; Premenopausal

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; BREAST TUMOR; ECONOMICS; FEMALE; HUMAN; MIDDLE AGED; NIGERIA; PATIENT COMPLIANCE; PREMENOPAUSE; PROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NIGERIA; PATIENT COMPLIANCE; PREMENOPAUSE; PROSPECTIVE STUDIES;

EID: 84866415081     PISSN: 11193077     EISSN: None     Source Type: Journal    
DOI: 10.4103/1119-3077.100618     Document Type: Article

References (26)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality: IARC cancer base No 10. Lyon France: International Agency for Research on Cancer; 2010. Available from http://globocan. iarc.fr
2. Solanke TF, Adebamowo CA. Report of the state of the art in oncology in Ibadan and Ife. UCH Ibadan: National headquarters of cancer registries in Nigeria; 1996.
3. Fregene A, Newman LA. Breast cancer in sub Saharan Africa; How does it relate to breast cancer in African American women? Cancer 2005;103:1540-50. (Pubitemid 40490014)
4. Oluwole SF, Fadiran OA, Odesami WO. Diseases of the breast in Nigeria. Br J Surg 1987;74:582-5. (Pubitemid 17102496)
5. Adesukanmi AR, Lawal OO, Adelusola KA, Durosimi MA. The severity, outcome and challenges of breast cancer in Nigeria. Breast 2006;15:399-409. (Pubitemid 43812214)
6. Atoyebi OA, Atimomo CE, Adesanya AA, Beredugo BK, da Rocha-Afodu JT. An appraisal of 100 patients with breast cancer seen at the Lagos University Teaching Hospital. Nig Q J Hosp Med 1997;7:104-8.
7. Anyanwu SN. Temporal trends in breast cancer presentation in the third world. J Exp Clin Cancer Res 2008;27:17.
8. Anyanwu SN. Survival following treatment of primary breast cancer in eastern Nigeria. East Afr Med J 2000;77:539-43. (Pubitemid 33249588)
9. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocol B-18 and B-27. J Clin Oncol 2008;26:778-85. (Pubitemid 351264391)
10. Marafz R, Beross G, Svebis M, Gyanti R, Vizhanyo R, Hajnal L, et al. Response rates following neoadjuvant chemotherapy and breast preserving treatment in patients with locally advanced breast cancer. Magy Seb 2005;58:225-32.
11. Beriwal S, Schwartz GF, Kumarnicky L, Garcia-Young JA. Breast conserving therapy after neoadjuvant chemotherapy: Long term results. Breast J 2006;12:159-64.
12. Anyanwu SNC, Egwuonwu OA, Ihekwoaba EC. Acceptance and adherence to treatment among breast cancer patients in Eastern Nigeria. Breast 2011;20(Suppl 2):s51-3.
13. Clegg-Lamptey J, Hodasi W. A study of breast cancer in Korle Bu Teaching Hospital: Assessing the impact of health education. Ghana Med J 2007;41:72-7.
14. Chintamani, Singhal V, Singh JP, Lyall A, Saxena S, Bansal A. Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer? - A prospective clinical study. BMC Cancer 2004;4:48.
15. Anyanwu SNC. Mylosuppresive effect of breast cancer chemotherapy on Nigerian patients. Nigerian Journal of Surgical Research 2000;2:81-87
16. Mamounas EP, Fisher B. Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 2001;28:389-99. (Pubitemid 32762082)
17. Moon YW, Rho SY, Jeung HC, Yang WI, Suh CO, Chung HC, et al. Neoadjuvant chemotherapy with infusional 5FU, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: An early response Predicts good prognosis. Ann Oncol 2005;16:1778-85. (Pubitemid 41631240)
18. Han HS, Reis IM, Zhao W, Kuroi K, Toi M, Suzuki E, et al. Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer 2011;47:2537-45.
19. Kirshner J, Hatch M, Hennessy DD, Fridman M, Tannous RE. Anemia in stage II and III breast cancer treated with adjuvant doxorubicin and Cyclophosphamide chemotherapy. Oncologist 2004;9:25-32. (Pubitemid 38134011)
20. Goldrick A, Olivotto IA, Alexander CS, Speers CH, Barnett J, Allan SJ, et al. Anemia is a common but neglected complication of adjuvant chemotherapy for early breast cancer. Curr Oncol 2007;14:227-33.
21. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-34. (Pubitemid 29479929)
22. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-5. (Pubitemid 11212891)
23. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483-96. (Pubitemid 20301179)
24. Reeler AV, Sikora K, Solomon B. Overcoming challenges in cancer treatment programmes in developing countries: A sustainable breast cancer initiative in Ethiopia. Clin Oncol 2008;20:191-8.
25. Sheppard VB, Christopher J, Nwabukwu I. Breaking the silence barrier: opportunity to address cancer in African-born women. J Natl Med Assoc 2010;102:461-8.
26. Yip CH, Smith RA, Anderson BO, Miller AB, Thomas DB, Ang ES, et al. Guideline implementation for breast healthcare in low and middle income countries. Cancer 2008;113(Suppl 8):2244-56.